An interventional study of Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor and Rhythm control and anticoagulation in Atrial Fibrillation, sponsored by Aswan University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Aswan University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Atrial Fibrillation with a site in Egypt — 9 open to participants now, 12 under way, 1 of them phase 3. Atrial Fibrillation · Egypt.
Among the 33 studies in Atrial Fibrillation with a site in Egypt, this one is the 18th largest by enrollment of the 21 interventional ones that give a count, is one of 6 that started in 2024, is one of 8 with no phase, and was the 21st registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →9 of the 33 studies in Atrial Fibrillation with a site in Egypt are open now. Recruiting first, the newest first:
University of L'Aquila · Sites in Egypt, Croatia, Denmark and 12 more countries
Ages 18+
Assiut University · Sites in Egypt
Ages 20–70 · Healthy volunteers
Helwan University · Sites in Egypt
Ages 18–74
Cairo University · Sites in Egypt
Ages 18+
Ain Shams University · Sites in Egypt
Ages 18–75
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 5 · Phase 4 4
First in 2007; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 180 across the 21 interventional studies, 200 across the 12 observational. Of the 15 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 33 have an industry lead sponsor. The 10 most frequent:
Aswan University is the lead sponsor of 47 studies on the registry; 21 are open to participants now.
Aswan University has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
3 of the studies in Atrial Fibrillation with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07640919Sohag UniversityPatterns of Cardiac Arrhythmia in Patients With Chronic Kidney Disease | 2026-12-20 |
| NCT06823466University of L'AquilaAdvancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants | 2027-02-12 |
| NCT07568964Ain Shams UniversityEvaluation of Probiotics' Effect on Atrial Fibrillation Recurrence in Patients Undergoing Cardioversion | 2027-05-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 33 studies in Atrial Fibrillation with a site in Egypt, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Investigators are going to assess direct effect of SGLT2 inhibitors on left atrial remodeling in participants with nonvalvular paroxysmal atrial fibrillation regardless of diabetes status.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients who will receive SGLT2 inhibitors
Drug: Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor · Drug: Rhythm control and anticoagulation
Patients who will receive Rhythm control +/- oral anticoagulation
Drug: Rhythm control and anticoagulation
10 mg of Dapagliflozin orally once daily
In acute stage: Cardioversion with D.C shock if haemodynamically unstable, after failure of pharmacological cardioversion or participant preference. or pharmacological cardioversion with either IV cordarone in structurally abnormal heart (150mg over 10 minutes followed by1 mg/min infusion for 6 hours followed by 0.5 mg/min not exceeding 2.4 grams over 24 hours till restoration of sinus Rhythm. Then maintenance dose of 200 mg tab orally every 8 hours for 3 weeks then 200 mg tab orally once per day. or Propafenone (Rytmonorm) 600 mg single oral dose in structurally normal heart then maintenance dose of 150mg tab orally every 8 hours. \+ Rivaroxaban 20mg orally once daily if CHA2DS2 VASc score 1 or more for males and 2 or more for females.
Left atrial remodeling
by measuring Indexed LA volume (LAVI) in ml/m2
Time frame: Before first administration of treatment and will be repeated 6 months after while still on treatment
Changes in left atrial strain
by measuring left atrial strain %
Time frame: Before first administration of treatment and will be repeated 6 months after while still on treatment
Changes in left atrial systolic force
by measuring left atrial systolic force in ml/m3
Time frame: Before first administration of treatment and will be repeated 6 months after while still on treatment
Mean percentage of time spent in atrial fibrillation
By documented ECG or Holter monitoring
Time frame: After the first dose of treatment till the end of the study (1 year)
Mortality Rate
all cause mortality
Time frame: After the first dose of treatment till the end of the study (1 year)
Incidence of Hospitalization due to HF
In hospital admission by HF symptoms
Time frame: After the first dose of treatment till the end of the study (1 year)
Number of participants with Stroke
Ischemic or hemorrhagic
Time frame: After the first dose of treatment till the end of the study (1 year)
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2024 to primary completion in Jun 2025, 10 months.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 10 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium/Glucose Cotransporter 2
Aswan University